Answers are grounded in this paper and cite their sources.
SAPHO syndrome is a rare disease that typically begins in the third-fifth decade of life, and is characterized by osteoarticular and dermatologic features [1]. The acronym summarizes the key clinical features: synovitis, acne, palmoplantar pustulosis, hyperostosis and osteitis [2]. The prevalence of this condition is estimated to be less than 1 per 10,000 people [3]. Several cases have been described in childhood, mostly in adolescents, some associated with other comorbidities. Indeed, the SAPHO clinical spectrum encompasses a wide range of different manifestations which overlap with other autoimmune or autoinflammatory disorders, thus often challenging the diagnosis, particularly in paediatric age [4–6]. If promptly recognized and adequately treated, SAPHO syndrome shows a favourable course. Herein we present a case series of 5 children affected by SAPHO syndrome, diagnosed at our Rheumatology Unit from March 2015 to June 2020, experiencing an excellent response to anti-TNFα. Five Caucasian patients (3 males) with a median age of 12 years and 5 months (range 132-192 months) received a diagnosis of SAPHO syndrome (Table 1). The median time between disease onset and diagnosis was 6 months (range 3–22 months). Patient #1 and #2 had a previous diagnosis of Inflammatory Bowel Diseases (IBD) – Crohn disease (CD) and Ulcerative colitis (UC), respectively; no other previous or concomitant relevant medical conditions were reported for the other patients.
No takes yet. Share an insight, caveat, or question.
Maccora et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: